HC Wainwright & Co. Maintains Buy on Can Fite Biofarma, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a 'Buy' rating on Can Fite Biofarma (AMEX:CANF), but has lowered the price target from $34 to $18.
October 24, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Can Fite Biofarma's price target has been lowered from $34 to $18 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a short-term negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100